Araujo-Castro Marta, Ruiz-Sánchez Jorge Gabriel, Gonzalvo César, Lamas Cristina, Parra Ramírez Paola, Martín Marcos-Rojas Patricia, Paja Miguel, Robles Lázaro Cristina, Michalopoulou Theodora, Tous María, Gonzalez-Boillos M, Recio-Córdova José María, Casteras Anna, Fernández-Álvarez Paula, Barca Tierno Verónica, Mulatero Paolo
Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), 28034 Madrid, Spain.
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1573-e1579. doi: 10.1210/clinem/dgae523.
It is estimated that about 5% of the primary aldosteronism (PA) cases are of hereditary origin (familial hyperaldosteronism, FH). To date, 4 forms of FH have been reported. However, in general little is known about the genetic causes that lead to the development of PA.
This work aimed to determine the rate of genetic testing for FH in the SPAIN-ALDO Registry and to describe the clinical characteristics of patients with FH. In addition, a literature review of reports of FH cases was performed.
A retrospective multicenter study of PA in patients followed in 35 Spanish tertiary hospitals (SPAIN-ALDO Registry).
Twenty-five of the 855 patients (3%) with PA included in the registry underwent genetic testing for FH, with complete results available for only 24 patients. However, we found that there were 57 patients who met the criteria for performing a genetic study of PA. Only 8 out of these 57 patients were genetically tested (14.0%), while the reasons to perform a genetic study in the remaining 17 genetically studied cases were quite heterogeneous. A positive result for FH was found in only one case for FH type III (KCNJ5 pathogenic variant). A systematic review of the literature was performed and identified a total of 25 articles reporting 246 patients with FH type I, 12 articles reporting 72 patients with FH type II, 14 articles reporting 29 cases of FH type III, and 3 articles reporting 12 patients with FH type IV.
The genetic study of FH is often scarce in real-world clinical practice, as 86% of patients with criteria to undergo genetic study were not evaluated in our cohort. Nevertheless, FH is an uncommon cause of PA, representing only 0.2% of cases in the SPAIN-ALDO Registry, although its prevalence may be as high as 4% among suspected cases.
据估计,约5%的原发性醛固酮增多症(PA)病例源于遗传(家族性醛固酮增多症,FH)。迄今为止,已报道了4种FH类型。然而,总体而言,导致PA发生的遗传原因知之甚少。
本研究旨在确定西班牙醛固酮增多症注册研究(SPAIN - ALDO Registry)中FH基因检测的比例,并描述FH患者的临床特征。此外,还对FH病例报告进行了文献综述。
对西班牙35家三级医院随访的PA患者进行回顾性多中心研究(SPAIN - ALDO Registry)。
注册研究中的855例PA患者中有25例(3%)接受了FH基因检测,仅有24例获得了完整结果。然而,我们发现有57例患者符合PA基因研究标准。这57例患者中只有8例进行了基因检测(14.0%),而其余17例进行基因研究的病例进行检测的原因相当多样。仅在1例III型FH(KCNJ5致病变异)中发现FH检测结果为阳性。进行了文献系统综述,共确定25篇报道246例I型FH患者的文章、12篇报道72例II型FH患者的文章、14篇报道29例III型FH病例的文章以及3篇报道12例IV型FH患者的文章。
在实际临床实践中,FH的基因研究往往较少,因为在我们的队列中,86%符合基因研究标准的患者未接受评估。尽管如此,FH是PA的罕见病因,在SPAIN - ALDO Registry中仅占病例的0.2%,尽管在疑似病例中其患病率可能高达4%。